PVI
ABUS icon

Pura Vida Investments’s Arbutus Biopharma ABUS Stock Holding History

Pura Vida Investments’s Portfolio ABUS Stock Details ABUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-100,000
Closed -$429K – 232
2021
Q3 		$429K Buy
+100,000
New +$333K 0.01% 255

Other funds holding ABUS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
BC
Brookfield Corp Toronto, Ontario, Canada $74.2B AUM 0.68% 1-Year Est. Return

Pura Vida Investments's ABUS Position: Q4 2021 in Review

Pura Vida Investments sold out of Arbutus Biopharma (ABUS) in Q4 2021, closing a stake of 100,000 shares — an estimated $429K sold.

Pura Vida Investments first reported a position in ABUS in Q3 2021 and held it in 1 quarter. The position peaked at $429K in Q3 2021. 122 funds tracked by Wall St. Rank hold ABUS as of Q4 2021.

  • Pura Vida Investments reported no remaining Arbutus Biopharma position as of Q4 2021 after selling out during the quarter.
  • Pura Vida Investments sold 100,000 Arbutus Biopharma shares in Q4 2021, an estimated $429K.
  • Pura Vida Investments first reported a position in Arbutus Biopharma in Q3 2021 and held it in 1 quarter.
  • Pura Vida Investments's Arbutus Biopharma position peaked at $429K in Q3 2021.
  • 122 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q4 2021.

Based on Pura Vida Investments's 13F filing for Q4 2021, filed 14 Feb 2022.